Literature DB >> 24218001

Are targeted therapies a consideration in poorly differentiated neuroendocrine tumors?

Steven Sorscher1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24218001      PMCID： PMC3825311          DOI： 10.1634/theoncologist.2013-0206

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  6 in total

1.  Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

Authors:  Marianne E Pavel; John D Hainsworth; Eric Baudin; Marc Peeters; Dieter Hörsch; Robert E Winkler; Judith Klimovsky; David Lebwohl; Valentine Jehl; Edward M Wolin; Kjell Öberg; Eric Van Cutsem; James C Yao
Journal:  Lancet       Date:  2011-11-25       Impact factor: 79.321

2.  Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges.

Authors:  Laura Catena; Emilio Bajetta; Massimo Milione; Monika Ducceschi; Monica Valente; Francesca Dominoni; Valentina Colonna
Journal:  Target Oncol       Date:  2011-04-06       Impact factor: 4.493

3.  Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity.

Authors:  J D Hainsworth; D H Johnson; F A Greco
Journal:  Ann Intern Med       Date:  1988-09-01       Impact factor: 25.391

4.  Neuroendocrine tumors.

Authors:  Matthew H Kulke; Al B Benson; Emily Bergsland; Jordan D Berlin; Lawrence S Blaszkowsky; Michael A Choti; Orlo H Clark; Gerard M Doherty; James Eason; Lyska Emerson; Paul F Engstrom; Whitney S Goldner; Martin J Heslin; Fouad Kandeel; Pamela L Kunz; Boris W Kuvshinoff; Jeffrey F Moley; Venu G Pillarisetty; Leonard Saltz; David E Schteingart; Manisha H Shah; Stephen Shibata; Jonathan R Strosberg; Jean-Nicolas Vauthey; Rebekah White; James C Yao; Deborah A Freedman-Cass; Mary A Dwyer
Journal:  J Natl Compr Canc Netw       Date:  2012-06-01       Impact factor: 11.908

Review 5.  Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned.

Authors:  James C Yao; Diane Reidy Lagunes; Matthew H Kulke
Journal:  Oncologist       Date:  2013-04-24

Review 6.  The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.

Authors:  Günter Klöppel; Aurel Perren; Philipp U Heitz
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.